EGFR and neoplasm: The preclinical studies showed that the half-maximal inhibitory concentration (IC50) of furmonertinib for EGFR ex20ins type was 5-10 times lower than that of EGFR wild, which indicates furmonertinib has shown encouraging anti-tumor activity in EGFR 20ins (8).